Hospitals and insurance companies now have an “early warning” tool that helps them stay abreast of new technologies that will impact the quality of patient care and cost of healthcare services

Lansdale, PA — April 28, 2008 — Today Hayes, Inc. launches Hayes TECHNOLOGY PROGNOSIS, an online, horizon-scanning service that provides hospitals, insurers, and policy makers with a forward-looking view of the changing health technology landscape.

TECHNOLOGY PROGNOSIS enables Hayes clients to stay abreast of new medical technologies, including drugs, biologics, devices, and procedures, up to 3 years before they enter the marketplace, as well as newly approved technologies that have not yet been widely adopted. It also tracks emerging technologies as they go through the regulatory approval process.

This subscription service includes four levels of horizon scanning, with the most in-depth being TECHNOLOGY PROGNOSIS Notes, which includes a summary of ongoing clinical trials, a review of available evidence, a perspective on the size of the potential market, a view of the likelihood and time frame of regulatory approval, as well as an overview of current technologies that will be impacted by the new drug or device.

In addition, TECHNOLOGY PROGNOSIS issues Quarterly Trend reports that give 5-year projections for a specific therapeutic area or service line. As an “early warning tool,” TECHNOLOGY PROGNOSIS is a vital resource for hospitals and insurers to use when developing their long-term technology and capital equipment planning strategies or anticipating impact on healthcare utilization.

“Health technology changes every day with the approval and introduction of new drugs, devices, and procedures. The challenge for our clients in the hospital and health insurance industries is determining which of these new technologies is really going to make a difference,” says Dr. Winifred Hayes, president and chief executive officer of Hayes, Inc. “TECHNOLOGY PROGNOSIS gives our clients the ability to make fully-informed decisions about health technologies with a complete 360 degree view of alternative treatments and products, including those that may not be available for several years into the future.”

Hayes TECHNOLOGY PROGNOSIS entries are prepared by an experienced, international team of medical analysts who scrutinize reports of early clinical research, technological developments, and FDA regulatory pipelines to determine which new technologies have the potential to significantly impact the quality of patient care or overall cost of healthcare versus those that are merely propelled by marketing hype.

Initially, TECHNOLOGY PROGNOSIS will include reports on 25 future technologies, including:

• New tests and drugs for prevention and treatment of MRSA (methicillin-resistant Staphylococcus aureus), including 3M’s BacLite® Rapid MRSA Test, as well as drug candidates such as Ceftobiprole from Basilea Pharmaceuticals and Telavancin developed by Theravance Inc.
• Less-invasive treatments for prostate cancer, including Sonablate 500® from Focus Surgery Inc. and Ablatherm High-Intensity Focused Ultrasound from EDAP TMS S.A.
• And new drugs such as Roche’s Zenapax® as a treatment for multiple sclerosis; Keryx Biopharmaceutical’s Sulonex ™ for the treatment of diabetic nephropathy; and Schering-Plough’s Sugammadex for the reversal of neuromuscular blockade.

When data are available, TECHNOLOGY PROGNOSIS also provides hospitals and payers with an analysis of the financial impact of these new technologies, including the associated costs such as training, staffing, and maintenance and replacement costs.

Dr. Hayes added, “With healthcare costs escalating rapidly in the United States, it is ever more important to make sure that every dollar invested today delivers real improvements in patient care and a return on investment for years to come. By helping our clients tune into those new products that will have a future impact on patient care, we drive better decision-making and reduce the risk of obsolescence.”

About Hayes, Inc.
Hayes, Inc. is the industry leader in providing independent, unbiased analyses of new healthcare technologies. Hayes offers evidence-based assessments, consulting services, and employee benefits that support good healthcare decisions and high-quality patient care. The company’s conclusions are independent, impartial, and objective, formulated by an international staff of medical analysts with expertise in a range of healthcare disciplines.

Hayes research and consulting services are used by some of the world’s leading healthcare organizations. More than 65% of U.S. healthcare insurers serving approximately 150 million lives depend on Hayes analyses when developing coverage policies. In addition, hospitals rely on Hayes research and consulting to support evidence-based decisions about health technology acquisition, and employers offer Hayes information to employees to help them deal with serious health conditions.

Hayes, Inc. was founded by Winifred S. Hayes, PhD, in 1989 and is headquartered in suburban Philadelphia.

For more information, please visit www.hayesinc.com.

Company Contact:
Karen Matthias
Hayes, Inc.
(614) 431-5510

Posted in Press Releases
This entry was posted on Tuesday, April 29th, 2008 at 8:39 am.